Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

IMPACTIVE Innovative Mechanochemical Processes to synthesize green ACTIVE pharmaceutical ingredients.

Coordinator
Universite De Montpellier, France
Runs
1 October 2022 to 30 September 2026
Status
Running
EU funding
€7.4m
Total cost
€7.7m
Partners
20 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101057286

What the project is doing

In the project's own words, from its summary on CORDIS.

The environmental impact of the pharmaceutical industry is a huge problem. The production and use of pharmaceuticals cause high CO2 emissions, contamination of soils, biota, and water, and even dangers to human health through carcinogenic impurities. Especially the use of solvents is a major problem. The European Green Deal has led to strict regulations on environmental pollution by the pharma industry, causing manufacturers to move outside of the EU due to the high costs associated with green pharma.

This results in supply chain fragility and low crisis preparedness in Europe. New methods to produce pharmaceuticals in a green, efficient, and economically friendly way are required. The IMPACTIVE project brings together the expertise and knowledge from two COST Actions and will develop novel green methods to produce active pharmaceutical ingredients (APIs) using mechanochemistry as a disruptive technology (as acknowledged by IUPAC).

Mechanochemistry uses mechanical processes, such as ball milling, twin-screw extrusion, resonant acoustic mixing, and spray drying, to induce chemical reactions. The advantages of mechanochemistry include: no solvent use, high efficiency, low costs, and reduced energy use and CO2 emission. Upon completion of the project, we will provide proof-of-concept at a small pilot scale of the use of mechanochemistry to produce 6 APIs from 3 different families of compounds.

Based on a recent study, switching to mechanochemistry can reduce terrestrial ecotoxicity and CO2 emissions by more than 85%, while production costs were reduced with 12%. The results of the IMPACTIVE project will thus enable pharmaceutical manufacturers to move back to Europe while minimizing environmental pollution. Through our strong dissemination and communication strategy we will ensure that the project?s results are shared with scientists, the pharmaceutical industry, and stakeholders from regulatory and public authorities to achieve maximum impact.

Topics

Who is involved

OrganisationCityCountryRole
Universite De MontpellierMontpellierFranceCoordinator
Universite Catholique De LouvainLouvain La NeuveBelgiumParticipant
Haute Ecole Specialisee De Suisse OccidentaleDelemontSwitzerlandAssociatedpartner
Novartis Pharma AGBaselSwitzerlandAssociatedpartner
Sigma-Aldrich Production GmbHBuchsSwitzerlandAssociatedpartner
Bundesanstalt Fuer Materialforschung Und -PruefungBerlinGermanyParticipant
Max Planck Institut Fuer KohlenforschungMuelheim An Der RuhrGermanyParticipant
Rheinisch-Westfaelische Technische Hochschule AachenAachenGermanyParticipant
Tallinna TehnikaülikoolTallinnEstoniaParticipant
Agata Comunicacion Cientifica SLSantanderSpainParticipant
Axlr Satt Occitanie MediterraneeMontpellierFranceParticipant
Ecole Nationale Superieure De Chimie De MontpellierMontpellier Cedex 5FranceThird party
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Technion - Israel Institute of TechnologyHaifaIsraelParticipant
Consorzio Interuniversitario Perlo Sviluppo Dei Sistemi a Grande InterfaseFirenzeItalyParticipant
Universita Degli Studi Di CagliariCagliariItalyThird party
Stichting Radboud UniversiteitNijmegenNetherlandsParticipant
Des Solutio - Solucoes E Consultoria Cientifica LdaCharneca De CaparicaPortugalParticipant
Ist-Id Associacao Do Instituto Superior Tecnico Para a Investigacao E O DesenvolvimentoLisboaPortugalParticipant
Johnson Matthey plcRoystonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI